4SA Stock Overview
A technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
AcouSort AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.80 |
52 Week High | kr2.34 |
52 Week Low | kr0.74 |
Beta | 0.65 |
1 Month Change | 6.68% |
3 Month Change | -29.07% |
1 Year Change | -35.12% |
3 Year Change | -69.25% |
5 Year Change | n/a |
Change since IPO | -66.93% |
Recent News & Updates
Recent updates
Shareholder Returns
4SA | DE Biotechs | DE Market | |
---|---|---|---|
7D | -2.4% | -1.2% | -1.0% |
1Y | -35.1% | -25.9% | 6.4% |
Return vs Industry: 4SA underperformed the German Biotechs industry which returned -25.9% over the past year.
Return vs Market: 4SA underperformed the German Market which returned 6.4% over the past year.
Price Volatility
4SA volatility | |
---|---|
4SA Average Weekly Movement | 9.9% |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.7% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4SA's share price has been volatile over the past 3 months.
Volatility Over Time: 4SA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 17 | Torsten Freltoft | www.acousort.com |
AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy.
AcouSort AB (publ) Fundamentals Summary
4SA fundamental statistics | |
---|---|
Market cap | €14.72m |
Earnings (TTM) | -€1.54m |
Revenue (TTM) | €836.39k |
17.6x
P/S Ratio-9.6x
P/E RatioIs 4SA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4SA income statement (TTM) | |
---|---|
Revenue | kr9.68m |
Cost of Revenue | kr1.23m |
Gross Profit | kr8.45m |
Other Expenses | kr26.23m |
Earnings | -kr17.78m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
Earnings per share (EPS) | -1.19 |
Gross Margin | 87.33% |
Net Profit Margin | -183.73% |
Debt/Equity Ratio | 0% |
How did 4SA perform over the long term?
See historical performance and comparison